Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company’s unusual business model. They discuss Dimerix’s Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the company and its partners. Dimerix’s pipeline is based on combining existing therapies with new drugs, a system it believes helps to lower risk to the company during the R&D phase. Dimerix’s lead compound is DMX-200, a Phase II chronic kidney disease treatment. DMX-200 is a combination of two existing drugs, irbesartan and propagermanium, which are already on the market in various regions around the world.
Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Kathy Harrison – CEO, Dimerix